We aimed to investigate the interaction between CD133 and Nestin and further assessed the correlation of CD133 and Nestin with clinicopathological characteristics and survival in patients with astrocytic tumor.
| INTRODUC TI ON
Astrocytic tumor is the most common glial tumor of the central nervous system, accounting for 13%-26% of intracranial tumors. 1 It is characterized by fast and invasive growth as well as no obvious boundary with normal brain tissue, which leads to short course of the disease and poor prognosis. 2 Currently, the treatment for astrocytic tumor relies on surgery, radiotherapy and chemotherapy. 1 Surgical resection is theoretically a cure for astrocytic tumor; however, due to the infiltration and frequent recurrence of the tumor, surgical resection is incomplete and ineffective in a proportion of cases, or even hard to be carried out when tumor grows in certain important areas such as brain stem. 3 Radiotherapy is the common therapy for almost all types of glial tumors including astrocytic tumor. However, only a few subtypes present high sensitivity to radiotherapy and the effect of radiation-induced necrosis on brain function should not be underestimated. [4] [5] [6] In addition, chemotherapy is limited to blood-brain barrier and side effects. Therefore, it is of clinical significance to explore potential biomarkers for disease monitoring and prognosis prediction, which would assist with treatment of astrocytic tumor.
In recent years, researchers discover the existence of cancer stem cells that have self-renewal and immense differentiation ability in astrocytic tumor. These cells are insensible and highly resistant to current radiotherapy and chemotherapy and contribute to the tumor metastasis and recurrence. 7, 8 Identification of cancer stem cells has been realized via a number of markers, and undoubtedly, the cancer stem cell markers provide a new direction for the treatment of astrocytic tumor and the prevention of recurrence. 9 CD133, a brain tumor stem cell marker, is shown to be upregulated in recurrent pilocytic astrocytoma, and suppression of CD133 increases cell chemosensitivity via inhibiting PI3K-Akt-NF-κB signaling mediators and MDR1. 10 In addition, the intermediate filament protein Nestin, which is critical in central nervous system development, is correlated with higher WHO grade and poor prognosis in patients with astrocytic tumor. 11, 12 However, current studies investigating the correlation of CD133 and Nestin with clinicopathological features and prognosis are mostly based on general glioma patients or astrocytic tumor patients in a specific pathological stage. Therefore, in this study, we evaluated the interaction between CD133 and Nestin and further assessed the correlation of CD133 and Nestin with clinicopathological characteristics and survival in patients with astrocytic tumor.
| MATERIAL S AND ME THODS

| Patients and tumor specimens
A total of 127 patients with astrocytic tumor who underwent surgical resection at our hospital between January 2005 and December 2011 were reviewed and analyzed in this study. All reviewed patients had (a) newly diagnosed as primary astrocytic tumor by pathological examination, (b) sufficient available tumor tissue for immunohistochemical analysis, (c) detailed clinical and follow-up data, and (d) without neoadjuvant therapy before surgery. All 127 human astrocytic tumor specimens were removed from surgical resection, confirmed by the pathology, fixed in the 10% neutral formaldehyde and embedded in paraffin wax. This study was approved by the Institutional Review Board of Shenzhen Nanshan People's Hospital. Written informed consents or verbal agreements with tape recording were collected from reviewed patients or their guardians.
| Data collection
The clinical data of studied cases were collected from the medical records, including age, gender and World Health Organization (WHO) grade. The assessment of WHO grade was based on the 2000 WHO classification of nervous system tumors, 13 and the WHO grade I and II astrocytic tumors were defined as low-grade astrocytic tumors (LGA), the WHO grade III and IV astrocytic tumors were defined as high-grade astrocytic tumors (HGA). The postoperative treatments including chemotherapy, radiotherapy (50-60Gy/5W), and immunotherapy were administered to patients based on the clinical status. All patients were followed up by telephone or clinic visit, with a median follow-up of 24.0 months (ranging from 2 to 113 months), and the survival data were extracted from the follow-up records, which were used to calculate the overall survival (OS).
| Immunohistochemistry (IHC) assay
The expression of CD133 and Nestin in astrocytic tumor tissue was analyzed by IHC staining, which was performed using the Rabbit anti-human CD133 monoclonal antibody (Cell Signaling Technology, Inc) and the Mouse anti-human Nestin monoclonal antibody (Santa Cruz Biotechnology, Inc) served as primary antibody, respectively.
IHC assay was carried out as follows: (a) formalin-fixed paraffin-embedded astrocytic tumor tissues were cut into 4 µm sections, then were baked in oven at 60℃ for 30 minutes; (b) deparaffinizing in xylene and rehydration in a graded series of ethanol were preformed;
(c) for antigen retrieval, the sections were placed in 0.01 mol/L citrate buffer (pH 6.0) and boiled for 20 minutes; (d) to block endogenous peroxidase, each section was incubated at room temperature with 3% H 2 O 2 for 10 minutes; (e) for immunoreaction, the section was incubated with primary antibody (Rabbit anti-human CD133 monoclonal antibody or Mouse anti-human Nestin monoclonal antibody) at 37℃ for 2 hours (negative control was incubated with phosphate buffer saline (PBS) instead of primary antibody); (f) after incubated with the primary antibody, the section was incubated with horseradish peroxidase-conjugated goat-anti-rabbit/goat-antimouse immunoglobulin G antibody (Santa Cruz Biotechnology, Inc);
(g) newly prepared diaminobenzidine (DAB) solution were added to each section for visualization; (h) the section was washed using distilled water, followed by the counterstaining with hematoxylin for 1 minute; and (i) after routine dehydration, transparency, drying and sealing, the section was observed on the microscope.
| IHC assessment
CD133 was a transmembrane protein, located in the cell membrane and cytoplasm. The positive staining cells showed immunoreactivity on the cell membranes and cytoplasm, presenting with brownyellow brighter than background color. The percentage of positive cells in ten randomly selected fields under 200× magnification was calculated. Nestin was located in the cytoplasm, and the positive staining cells was presented as reddish-brown granules in the cytoplasm. Under 200× magnification, the percentage of positive cells in ten randomly selected fields was calculated as well. Both CD133 and Nestin staining were semi-quantitatively graded for the percentage of positive tumor cells as the method that previous studies report 14, 15 : negative (0%): no tumor cell was positively stained; low (<30%): <30% of the tumor cells were positively stained; moderate (30%-60%): 30%-60% of the tumor cells were positively stained; high (≥60%): ≥60% of the tumor cells were positively stained. 
| Statistical analysis
| RE SULTS
| Correlation of CD133 and Nestin with clinical features
There were 79 (62.2%), 34 (26.8%), 14 (11.0%), and 0 (0.0%) patients with CD133 negative, low, moderate, and high expression, respectively. CD133 expression was correlated with advanced WHO grade (P < .001) (Table 1, Figure 1A ). However, no correlation was observed between CD133 and age (P = .566) or gender (P = .115). As for Nestin, 7 (5.5%), 47 (37.0%), 20 (15.7%), and 53 (41.7%) patients were with Nestin negative, low, moderate, and high expression, respectively. Nestin was associated with advanced WHO grade (P < .001) (Table 1, Figure 1B ). However, no correlation was observed between Nestin and age (P = .628), gender (P = .056).
| Correlation of CD133 with Nestin
In order to determine the interaction between CD133 and Nestin, Spearman's rank correlation test was performed, which observed that CD133 expression was positively correlated with Nestin expression in astrocytic tumor tissue (P < .001, r = .299) ( Table 2 ).
| Correlation of CD133 and Nestin with OS
Patients with CD133 moderate expression presented with the lowest OS, followed by patients with CD133 low expression, and patients with CD133 negative, further analysis illustrated that CD133 was negatively correlated with OS (P < .001) ( Figure 2A ). Regarding with OS (P < .001) ( Figure 2B ). 
TA B L E 1 Correlation of CD133 and Nestin expressions with clinical characteristics
| Factors affecting OS
| Correlation of CD133 and Nestin with OS in LGA patients and HGA patients
The correlation of CD133 and Nestin with OS were then evaluated separately in LGA patients and HGA patients. In LGA patients, CD133 was not correlated with OS (P = .775) ( Figure 3A) , whereas
Nestin was negatively correlated with OS (P = .004) ( Figure 3B ).
In HGA patients, both CD133 (P = .012) ( Figure 3C ) and Nestin (P = .011) ( Figure 3D ) were negatively associated with OS. (Table 5 ).
| Factors affecting OS in LGA patients and HGA patients
| D ISCUSS I ON
There are a small population of highly tumorigenic cancer stem cells existed in a variety of malignancies including astrocytic tumor. 7 The presence of cancer stem cells drives the invasiveness of tumor and resistance to therapies, which is crucial for tumor metastasis and relapse. 8 The isolation of cancer stem cells is achieved via specific stem cell-related surface antigens, and the abundance of these cancer stem cell markers are shown to be closely related with cancer development and progression. 9 For instance, the transmembrane glycoprotein CD133 has been used to identify cancer stem cells in different solid tumors including brain, lung, gastric, and liver cancers. 16 In brain tumors, CD133 is first used to identify cancer stem cells in pediatric samples of glioma and medulloblastoma, and CD133 positive tumor cells are more aggressive and with higher capacity to self-renew. 9, 17 And in astrocytic tumor, CD133 expression is correlated with higher histological grade and larger tumor size. 18 In addition, Nestin is one of the type VI intermediate filament proteins. It regulates the stemness of different cancer cells and promotes tumor invasion and metastasis. 14 In astrocytic tumors, Nestin is abundantly expressed in undifferentiated stem cells and progenitors cells, and it is associated with increased WHO grade, but not with patient's gender, age, tumor location or tumor size. 19 Besides, Nestin positive glioblastoma cells show increased tumor sphere-forming ability and tumor sphere size and is correlated with high grades of malignancy in glioblastoma. 20 However, the patients enrolled in these previous studies were mostly general glioma patients or with certain histological subtype of astrocytic tumors, and the sample sizes were relatively small. Thus, we recruited a larger number of patients with astrocytic tumor, and our study reported that CD133
and Nestin expressions were both correlated with advanced WHO grade but not with age or gender in patients with astrocytic tumor. In addition, positive correlation was also observed between LGA, low-grade astrocytic tumors; HGA, high-grade astrocytic tumors cancer, colorectal cancer, pancreatic cancer, etc. [21] [22] [23] In addition, the negative impact of Nestin on survival has also been observed in lung cancer, esophageal squamous cancer, bladder cancer, etc. [24] [25] [26] Whereas in astrocytic tumor, the tumor of the central nervous system, the effects of CD133 and Nestin on prognosis are only discovered in a small volume of literatures. 18, 19 Therefore, this present study recruited relatively more patients with astrocytic tumor compared with the previous literatures and aimed to further validate the clinical relevance of CD133 and Nestin in astrocytic tumor regarding their impact on survival. We disclosed that CD133 and Nestin both predicted poor OS in patients with astrocytic tumor.
The possible reasons are as follows: (a) CD133 high expression is a sign of cancer stem cell activity that increases cell differentiation and proliferation, which contributes to tumor progression; Nestin is previously shown to delineate invasion of astrocytic tumor into the adjacent gray and white matter; therefore, Nestin is associated with aggressive tumor behavior, which leads to higher pathological grade and poor prognosis in patients with astrocytic tumor. 14, 16 (b) Increased stemness is also shown to induce resistance to chemotherapy and radiotherapy, which leads to poor prognosis in patients with astrocytic tumor. 10 In subgroup analysis, CD133 was correlated with poor OS in HGA Abbreviations: CI, confidence; HGA, high-grade astrocytic tumor (WHO grade III ~ IV); HR, hazard ratio; OS, overall survival; WHO, World Health Organization. a CD133 and Nestin expression were included in the Cox's regression in the form of ordered categorical variable, which were encoded as: negative (0%) = 0, low (0%-30%) = 1, moderate (30%-60%) = 2, high (≥60%) = 3.
needed to further validate our findings. Additionally, due to relatively early patient enrollment time, WHO classification 2000 was used for tumor evaluation, which was a bit old compared with the newly launched WHO classification 2016. However, due to lack of cytogenic and molecular genetics information, re-evaluation of the tumors using the 2016 classification was not feasible. And the correlation of IDH mutation with CD133 and Nestin as well as survival was not assessed.
In conclusion, CD133 and Nestin are correlated with advanced WHO grade and poor survival in patients with astrocytic tumor, which benefits the exploration of prognostic factor for astrocytic tumor.
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